1.Cherubin, C, Sapira, J. The medical complications of drug addiction and the medical assessment of the intravenous drug user. Annals of Internal Medicine 1993; 119: 1017–1028.
2.Del Guidice, P. Cutaneous complication of intravenous drug abuse. British Journal of Dermatology 2004; 150: 1–10.
3.Lloyd-Smith, E, et al. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2008; 8: 405.
4.Salmon, AM, et al. Injecting-related injury and disease among clients of a supervised injecting facility. Drug & Alcohol Dependence 2009; 101: 132–136.
5.Takahasi, T, et al. Type and location of injection drug use-related soft tissue infections predict hospitalization. Journal of Urban Health 2003; 80: 127–136.
6.Biswanger, I, et al. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Fransisco. Clinical Infectious Diseases 2000; 30: 579–581.
7.Lloyd-Smith, E, et al. Prevalence and correlates of abscesses among a cohort of injection drug users. Harm Reduction Journal 2005; 2: 24.
8.Hope, V, et al. Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infectious Diseases 2008; 8: 120.
9.Kerr, T, et al. High rates of primary care and emergency department use among injection drug users in Vancouver. Journal of Public Health (Oxford) 2005; 27: 62–66.
10.Palepu, A, et al. Hospital utilization and costs in a cohort of injection drug users. Canadian Medical Association Journal 2001; 165: 415–420.
11.Murphy, E, et al. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clinical Infectious Diseases 2001; 33: 35–40.
12.Vlahov, D, et al. Bacterial infections and skin cleaning prior to infection among intreavenous drug users. Public Health Reports 1992; 107: 595–598.
13.Dwyer, R, et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug & Alcohol Dependence 2009; 100: 9–16.
14.Topp, L, et al. Prevalence and predictors of injecting-related injury and disease among clients of Australia's needle and syringe programs. Australia & New Zealand Journal of Public Health 2008; 32: 34–37.
15.Spijkerman, I, van Ameijden, EJ, Mientjes, G. Human immunodeficiency virus and other risk factors for skin abscesses and endocarditis among injection drug users. Journal of Clinical Epidemiology 1996; 49: 1149–1154.
16.Darke, S, Ross, J, Kaye, S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug & Alcohol Dependence 2001; 62: 77–82.
17.Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG. Shooting Up: Infections Among Injecting Drug Users in the United Kingdom 2007. London: Health Protection Agency, October, 2008.
18.Lamagni, TL, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003–2004. Emerging Infectious Diseases 2008; 14: 202–209.
19.Irish, C, et al. Skin and soft tissue infections and vascular disease among drug users, England [Letter]. Emerging Infectious Diseases 2007; 13 (October).
20.Jones, JA, et al. An outbreak of serious illness and death among injecting drug users in England and Wales during 2000. Journal of Medical Microbiology, 2002; 51: 978–984.
21.Beeching, NJ, Crowcroft, NS. Tetanus in injecting drug users. The latest Clostridium infection to threaten injectors in Britain. British Medical Journal 2005; 330: 208–209.
22.Akbulut, D, et al. Outbreak report: Wound botulism in injectors of illicit drugs: upsurge in cases in England during 2004. Eurosurveillance Monthly 2005; 10 (September).
23.Kearns, AM, et al. An unusual clone of MRSA causing infection in injecting drug users. Journal of Infection 2004; 49: 49–50.
24.Morrison, A, Elliott, L, Gruer, L. Injecting-related harm and treatment seeking behaviour among injecting drug users. Addiction 1997; 92: 1349–1352.
25.Noone, A, et al. HIV infection in injecting drug users attending centres in England and Wales, 1990–1991. AIDS 1993; 7: 1501–1507.
26.Gordon, L, et al. The Economic and Social Costs of Class A Drug use in England and Wales, 2003/04. In: Singleton, N, Murray, R, Tinsley, L, eds. Measuring different aspects of problem drug use: methodological developments. London, Home Office, 2006. Home Office Online Report, 16/06.
27.Ciccarone, D, et al. Soft tissue infections among injection drug users-San Francisco, California, 1996–2000. Morbidity & Mortality Weekly Reports: CDC Surveillance Summaries 2001; 50: 381–384.
28.French, M, et al. Chronic illicit drug use, health services utilisation and the cost of medical care.Social Science & Medicine 2000; 50: 1703–1713.
29.van Beek, I, Dwyer, R, Malcom, A. Cocaine injecting: the sharp end of drug related harm! Drug & Alcohol Review 2001; 20 (Harm Reduction Digest 14): 333–342.
30.Harris, H, Young, D, Organ, C Jr.. Care of injection drug users with soft tissue infections in San Fransisco, California. Archives of Surgery 2002; 137: 1217–1222.
31.Grau, L, et al. Expanding harm reduction services through a wound and abscess clinic. American Journal of Public Health 2002; 92: 1915–1917.
32.Rhodes, T, et al. Groin injecting in the context of crack cocaine and homelessness: From ‘risk boundary’ to ‘acceptable risk’? International Journal of Drug Policy 2006; 17: 164–170.
33.Rhodes, T, et al. Crack-heroin speedball injection and its implications for vein care: qualitative study. Addiction 2007; 102: 1782–1789.
34.Hope, VD, Hickman, M, Tilling, K. Capturing crack-cocaine use: Estimating the prevalence of Crack-cocaine use in London using capture-recapture with covariates. Addiction 2005; 100: 1701–1708.
35.Van Den Berg, C, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454–1462.
36.Vickerman, P, Hickman, M, Judd, A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. International Journal of Epidemiology 2007; 36: 396–405.
37.Craine, N, et al. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiology and Infection 2009; 137: 1255–1265.
38.NICE. Needle and syringe programmes: providing people who inject drugs with injecting equipment. National Institute for Health and Clinical Excellence, Public Health Guidance, PH18, February 2009 (http://guidance.nice.org.uk/PH18). 39.Harm Reduction Works. National Treatment Agency for Substance Use and Exchange Supplies. (www.harmreductionworks.org.uk/). Accessed 17 August 2009.
40.Hickman, M, et al. Hepatitis C (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. Journal of Viral Hepatitis 2007; 14: 645–652.